New Preclinical Study Finds Niagen® Corrects Social Deficits in Mouse Model of Autism

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #AutismResearch--ChromaDex Corp. (NASDAQ:CDXC) today announced the results of a new preclinical study published in Nature Scientific Reports investigating the role of Niagen® (patented nicotinamide riboside) in addressing social deficits in Autism Spectrum Disorder (ASD). This new study joins a growing body of preclinical data demonstrating that boosting NAD+ (nicotinamide adenine dinucleotide) levels may have a positive effect on cognitive health. The study was the first to evalua

Click to view original post